Mifepristone: An overview for Australian practice

Australian Prescriber

Volumn 32, Issue 6, 2009, Pages 152-154

  Healy, David L ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Cushing's syndrome; Meningioma; Pregnancy; Progesterone; Progestogen; RU486; Therapeutic abortion

Indexed keywords

ANDROGEN RECEPTOR; DEXAMETHASONE; ESTRADIOL RECEPTOR; ESTROGEN RECEPTOR; GEMEPROST; GLUCOCORTICOID RECEPTOR; LEVONORGESTREL; METHOTREXATE; MIFEPRISTONE; MINERALOCORTICOID RECEPTOR; MISOPROSTOL; PLACEBO; PROGESTERONE; PROGESTERONE RECEPTOR; TESTOSTERONE;

ADVANCED CANCER; AUSTRALIA; BLEEDING; BREAST CANCER; BREAST CARCINOMA; CANCER INHIBITION; CANCER PATIENT; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CUSHING SYNDROME; DIARRHEA; DRUG ABSORPTION; DRUG ACTIVITY; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; EMERGENCY CONTRACEPTION; ENDOMETRIUM HYPERPLASIA; FETUS DEATH; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; INTERMETHOD COMPARISON; LABOR INDUCTION; MEDICAL ABORTION; MENINGIOMA; MONOTHERAPY; NAUSEA; NONHUMAN; PATIENT DECISION MAKING; PREGNANCY TERMINATION; RECEPTOR AFFINITY; RECOMMENDED DRUG DOSE; REVIEW; SECOND TRIMESTER PREGNANCY; SURGICAL ABORTION; THIRD TRIMESTER PREGNANCY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR MODEL; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; UTERUS MYOMA; VOMITING;

EID: 73949094673     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2009.076     Document Type: Review

References (18)

1. Healy DL, Baulieu EE , Hodgen GD. Induction of menstruation by an antiprogesterone steroid (RU486) in primates: site of action, dose-response relationships, and hormonal effects. Fertil Steril 1983;40:253-7.
2. Khanna J, Van Look PFA, Griffin PD, editors. Challenges in reproductive health research: biennial report, 1992-1993. Geneva: World Health Organization; 1994.
3. McKinley C, Thong KJ, Baird DT. Pregnancy: the effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol. Hum Reprod 1993;8:1502-5.
4. World Health Organization Task Force on post-ovulatory methods of fertility regulation. Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. BJOG 2000;107:524-30.
5. World Health Organization. Safe abortion: technical and policy guidance for health systems. Geneva: WHO; 2003.
6. T ermination of pregnancy. A resource for health professionals. Melbourne: The Royal Australian and New Zealand College of Obstetricians and Gynaecologists; 2005. www.ranzcog.edu.au/womenshealth/pdfs/Termination- ofpregnancy. pdf [cited 2009 Nov 12]
7. Macnaughton M. The abortion pill (mifepristone/RU486): widening the choice for women. London: Birth Control Trust;1990.
8. Mamers PM, Lavelle AL, Evans AJ, Bell SM, Rusden JR, Healy DL. Women's satisfaction with medical abortion with RU486. Med J Aust 1997;167:316-7.
9. Ashok PW, Kidd A, Flett GM, Fitzmaurice A, Graham W, Templeton A. A randomized comparison of medical abortion and surgical vacuum aspiration at 10-13 weeks gestation. Hum Reprod 2002;17:92-8.
10. Royal College of Obstetricians and Gynaecologists. The care of women requesting induced abortion. London; RCOG: 2004. www.rcog.org.uk/womens-health/ clinical-guidance/carewomen-requesting-induced-abortion [cited 2009 Nov 12)
11. Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Task force on postovulatory methods of fertility regulation. Lancet 1999;353:697-702.
12. Bagaria M, Suneja A, Vaid NB, Guleria K, Mishra K. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. Aust N Z J Obstet Gynaecol 2009;49:77-83.
13. Johanssen S, Allolio B. Mifepristone (RU 486) in Cushing's syndrome. Eur J Endocrinol 2007;157:561-9.
14. Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, et al. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest 2006;24:727-33.
15. Perrault D, Eisenhauer EA, Pritchard KI, Panasci L, Norris B, Vandenberg T, et al. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1996;14:2709-12.
16. Wilkens J, Chwalisz K, Han C, Walker J, Cameron IT, Ingamells S, et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab 2008;93:4664-71.
17. Grimes DA. Risks of mifepristone abortion in context. Contraception 2005;71:161.
18. Parliament of Australia Senate. Inquiry into Therapeutic Goods Amendment (Repeal of Ministerial responsibility for approval of RU486) Bill 2005. 2006 Feb 8. www.aph.gov.au/senate/committee/clac-ctte/completed-inquiries/2004-07/ru486/ report/index.htm [cited 2009 Nov 12)